Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16


Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study.

Charlier C, Perrodeau É, Leclercq A, Cazenave B, Pilmis B, Henry B, Lopes A, Maury MM, Moura A, Goffinet F, Dieye HB, Thouvenot P, Ungeheuer MN, Tourdjman M, Goulet V, de Valk H, Lortholary O, Ravaud P, Lecuit M; MONALISA study group.

Lancet Infect Dis. 2017 May;17(5):510-519. doi: 10.1016/S1473-3099(16)30521-7. Epub 2017 Jan 28.


Tenofovir DF/emtricitabine and efavirenz combination therapy for HIV infection in patients treated for tuberculosis: the ANRS 129 BKVIR trial.

Lortholary O, Roussillon C, Boucherie C, Padoin C, Chaix ML, Breton G, Rami A, Veziris N, Patey O, Caumes E, May T, Molina JM, Robert J, Tod M, Fagard C, Chêne G; ANRS 129 BKVIR Trial Group.

J Antimicrob Chemother. 2016 Mar;71(3):783-93. doi: 10.1093/jac/dkv384. Epub 2015 Dec 17.


Combined ART started during acute HIV infection protects central memory CD4+ T cells and can induce remission.

Chéret A, Bacchus-Souffan C, Avettand-Fenoël V, Mélard A, Nembot G, Blanc C, Samri A, Sáez-Cirión A, Hocqueloux L, Lascoux-Combe C, Allavena C, Goujard C, Valantin MA, Leplatois A, Meyer L, Rouzioux C, Autran B; OPTIPRIM ANRS-147 Study Group.

J Antimicrob Chemother. 2015 Jul;70(7):2108-20. doi: 10.1093/jac/dkv084. Epub 2015 Apr 21.


Does transient cART started during primary HIV infection undermine the long-term immunologic and virologic response on cART resumption?

Krastinova E, Seng R, Lechenadec J, Panjo H, Essat A, Makhloufi D, Obadia M, Bernard L, Goujard C, Meyer L; ANRS PRIMO cohort.

BMC Infect Dis. 2015 Apr 10;15:178. doi: 10.1186/s12879-015-0892-1.


Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial.

Chéret A, Nembot G, Mélard A, Lascoux C, Slama L, Miailhes P, Yeni P, Abel S, Avettand-Fenoel V, Venet A, Chaix ML, Molina JM, Katlama C, Goujard C, Tamalet C, Raffi F, Lafeuillade A, Reynes J, Ravaux I, Hoën B, Delfraissy JF, Meyer L, Rouzioux C; OPTIPRIM ANRS Study Group.

Lancet Infect Dis. 2015 Apr;15(4):387-96. doi: 10.1016/S1473-3099(15)70021-6. Epub 2015 Feb 18.


Is clinical practice concordant with the changes in guidelines for antiretroviral therapy initiation during primary and chronic HIV-1 infection? The ANRS PRIMO and COPANA cohorts.

Krastinova E, Seng R, Yeni P, Viard JP, Vittecoq D, Lascoux-Combe C, Fourn E, Pahlavan G, Delfraissy JF, Goujard C, Meyer L; ANRS PRIMO and COPANA Cohorts.

PLoS One. 2013 Aug 1;8(8):e71473. doi: 10.1371/journal.pone.0071473. Print 2013. Erratum in: PLoS One. 2013;8(11). doi:10.1371/annotation/aed12a66-9c76-4e49-806b-881a2fe23bba. Goujard, Cecile [added].


Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL in 2009: a French nationwide study.

Assoumou L, Descamps D, Yerly S, Dos Santos G, Marcelin AG, Delaugerre C, Morand-Joubert L, Ruffault A, Izopet J, Plantier JC, Pakianather S, Montes B, Chaix ML, Wirden M, Costagliola D, Masquelier B; ANRS AC11 Resistance Group.

J Antimicrob Chemother. 2013 Jun;68(6):1400-5. doi: 10.1093/jac/dkt033. Epub 2013 Feb 12.


Long-term immunogenicity of two doses of 2009 A/H1N1v vaccine with and without AS03(A) adjuvant in HIV-1-infected adults.

Durier C, Desaint C, Lucht F, Girard PM, Lévy Y, May T, Michelet C, Rami A, Roman F, Delfraissy JF, Aboulker JP, Launay O; ANRS 151 study group and the REIVAC network.

AIDS. 2013 Jan 2;27(1):87-93. doi: 10.1097/QAD.0b013e328359f27a.


Pneumocystis jirovecii colonization and infection among non HIV-infected patients.

Fily F, Lachkar S, Thiberville L, Favennec L, Caron F.

Med Mal Infect. 2011 Oct;41(10):526-31. doi: 10.1016/j.medmal.2011.07.006. Epub 2011 Aug 23.


Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial.

Launay O, Desaint C, Durier C, Loulergue P, Duval X, Jacomet C, Pialoux G, Ghosn J, Raffi F, Rey D, Ajana F, Colin de Verdière N, Reynes J, Foubert V, Roman F, Devaster JM, Delfraissy JF, Aboulker JP; ANRS 151 HIFLUVAC Study Group and the French Clinical Vaccinology Network (Réseau National d'Investigation Clinique en Vaccinologie REIVAC).

J Infect Dis. 2011 Jul 1;204(1):124-34. doi: 10.1093/infdis/jir211.


HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy.

Lanoy E, Rosenberg PS, Fily F, Lascaux AS, Martinez V, Partisani M, Poizot-Martin I, Rouveix E, Engels EA, Costagliola D, Goedert JJ; FHDH-ANRS CO4.

Blood. 2011 Jul 7;118(1):44-9. doi: 10.1182/blood-2011-02-339275. Epub 2011 May 6.


Deep brain stimulation hardware-related infections: a report of 12 cases and review of the literature.

Fily F, Haegelen C, Tattevin P, Buffet-Bataillon S, Revest M, Cady A, Michelet C.

Clin Infect Dis. 2011 Apr 15;52(8):1020-3. doi: 10.1093/cid/cir065. Review.


Should we systematically perform central nervous system imaging in patients with Whipple's endocarditis?

Besnard S, Cady A, Flecher E, Fily F, Revest M, Arvieux C, Donnio PY, Michelet C, Tattevin P.

Am J Med. 2010 Oct;123(10):962.e1-4. doi: 10.1016/j.amjmed.2010.04.030.


Short report: Incidence of yellow fever vaccine-associated neurotropic disease.

Guimard T, Minjolle S, Polard E, Fily F, Zeller H, Michelet C, Tattevin P.

Am J Trop Med Hyg. 2009 Dec;81(6):1141-3. doi: 10.4269/ajtmh.2009.09-0295.


Observational studies of salvage treatment for persistent bacteremia: beware of survivor treatment selection bias.

Tattevin P, Uhel F, Fily F.

Clin Infect Dis. 2009 Dec 15;49(12):1960; author reply 1961. doi: 10.1086/648500. No abstract available.


[Diarrhea revealing AIDS in an octogenarian].

Kerleau K, Fily F, Lecomte F, Kerleau JM, Lévesque H, Courtois H.

Rev Med Interne. 2004 Mar;25(3):245-7. French. No abstract available.


Supplemental Content

Loading ...
Support Center